Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives

Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives Monument Tx announce first-in-human clinical study for MT1980, a novel treatment for neuroinflammation, shows drug can access the brain San Francisco, USA, January 8, 2023: Monument Therapeutics, a stratified neuroscience company, will this week […]

Emotional bias training as a treatment for anxiety and depression: evidence from experimental medicine studies in healthy and medicated samples

Anxiety and depression are leading causes of disability worldwide, yet individuals are often unable to access appropriate treatment. There is a need to develop effective interventions that can be delivered remotely. Previous research has suggested that emotional processing biases are a potential target for intervention, and these may be altered through brief training programs.

Using Affective Cognition to Enhance Precision Psychiatry

Major depressive disorder affects hundreds of millions of people, is among the leading causes of disability worldwide. While a range of effective drugs are available, the majority of patients do not achieve symptomatic remission. Precision psychiatry offers a range of exciting possibilities for optimizing effective prevention, diagnosis, and treatment of psychiatric disorders.

Assessing cognitive function in clinical trials of schizophrenia

Cognitive dysfunction in schizophrenia is an important target for novel therapies. Computerised cognitive assessment may optimise the statistical power of cognitive trials by reducing measurement error and between-site variability and decreasing patient attrition through increased tolerability.

Effects of 7.5% Carbon Dioxide and Nicotine Administration on Latent Inhibition

Here, two complementary experimental studies suggest latent inhibition is modified by manipulations that are relevant to the detection and treatment of schizophrenia. These results suggest that this latent inhibition task merits further investigation in the context of neurobiological sub-groups suitable for novel treatment strategies.

Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference

Stratified medicine company Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference   Manchester, UK, August 02, 2022: Monument Therapeutics, a stratified medicine company, announced at the British Association for Psychopharmacology conference, positive preclinical results supporting the use of their proprietary non-invasive digital biomarker and drug MT1988 to treat […]

Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation

Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation Monument Tx announce first-in-human study of MT1980, a novel treatment for neuroinflammation Manchester, UK, June 13, 2022: Monument Therapeutics, a stratified medicine company, today announced that their first-in-human Phase I study of MT1980, a novel […]

We are attending the BIO Conference: join us at two exciting sessions

We will be participating at the upcoming Biotechnology Innovation Organization conference taking place in San Diego, California, June 13-16. Members of our team will be speaking at two incredibly exciting sessions: Tackling Post-Covid Cognitive Impairment     Wednesday, June 15th, 4:15pm – 5:15pm PDT https://www.bio.org/events/bio-international-convention/sessions/916081 Speaker: Dr Kiri Granger, Monument Tx, CSO Widespread evidence shows that cognitive problems are the […]

Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)

Proud that our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (#POCD). As the article notes, estimates suggest that the overall incidence of POCD in older patients can be as high as 50-80% at discharge, 20-50% at six weeks and 10-30% at six months post-surgery. New therapies are […]

Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’!

We are very proud that our fantastic CSO Dr Kiri Granger has been listed as one of In Vivo‘s 2022 ‘Rising Leaders’! The third annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care. Included for 2022 are investors, CEOs of small and mid-sized […]

Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA

Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA. Don’t miss her in-person talk: Using Digital Biomarkers to Apply a Stratified Approach to Neuroinflammation When: April 19th, 9AM EST Synopsis Applying digital biomarkers, in combination with standard inflammatory markers, to aid identification of people at high […]

Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference

Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference  Monument Tx CSO to present preclinical data for lipid reformulation of anti-inflammatory compound MT1980 at AD/PD conference in Barcelona 15-20th March 2022 Manchester, UK, March 14, 2022: Monument Therapeutics, a stratified medicine company, today announced it will be […]

Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference

Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference Monument Tx CSO to present novel biomarker predicting risk for developing POCD at AD/PD conference in Barcelona 15-20th March 2022 Manchester, UK, March 14, 2022: Monument Therapeutics, a stratified medicine company, today announced it will […]

Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic

Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic Lipid reformulation of anti-inflammatory compound MT1980 for POCD accelerating into clinic in 2022 Manchester, UK, Dec 14, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised an additional £0.5 million to accelerate the development of its anti- neuroinflammation compound MT1980, […]

Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study

Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study Aim to bring novel digital biomarker-drug combination that overcomes biological heterogeneity challenge to clinic by 2022 Manchester, UK, September 20, 2021: Monument Therapeutics, a stratified medicine company, today announced a pioneering preclinical study to support the use of their proprietary non-invasive biomarker for […]

New Interview in Scrip

New interview in Scrip! Read more about our novel approach to CNS drug development and our focus on repurposing existing drugs with the aid of digital biomarkers. Read the interview here. For further information, contact: Jenny Barnett, CEO E: jbarnett@monumenttx.com Media: Richard Hayhurst/Janet Joy E: Richard@rhapr.eu or jan@rhapr.eu Tel: +44 7711 821527 Notes to Editors: […]

Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director

Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director Julian brings deep expertise in the development and commercialising of repurposed and reprofiled compounds. He was co-founder and CEO of Acacia Pharma Group plc, a hospital pharmaceuticals company which launched its lead product BARHEMSYS®, a repurposed […]

Digital brain biomarker company Monument Therapeutics raises £2.6 million

Cambridge Cognition spin-out targets schizophrenia and post-operative cognitive dysfunction Manchester, UK, July 1st, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised £2.625 million in seed funding to spin out of Cambridge Cognition Ltd and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug […]

Richard Bungay Joins the Board as a Director

Change of Director – 22nd April 2021 Monument Therapeutics is pleased to announce that Richard Bungay will join the Board as a Director with immediate effect. Mr. Bungay has over 25 years’ experience in corporate roles with R&D-based companies within the biotechnology and pharmaceutical sector, including as CFO of both public and private companies, with […]